GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Fenrigul JoJobei
Country: Mozambique
Language: English (Spanish)
Genre: Photos
Published (Last): 1 November 2005
Pages: 486
PDF File Size: 17.30 Mb
ePub File Size: 17.58 Mb
ISBN: 736-1-26299-182-4
Downloads: 73663
Price: Free* [*Free Regsitration Required]
Uploader: Kale

Magnesium peroxide The therapeutic efficacy of Magnesium peroxide can be msdds when used in combination with Glycopyrronium. Oxymorphone The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxymorphone. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Neostigmine.

Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Glycopyrronium.

U Muscarinic acetylcholine receptor M2. Capreomycin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Capreomycin.

The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Cannabidiol. Pentazocine The risk or severity of adverse effects can be increased when Glycopyrronium is combined glycopyrrolste Pentazocine.

Hydroflumethiazide The serum concentration of Hydroflumethiazide can be increased when it is combined with Glycopyrronium.

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Edrophonium. Calcium polycarbophil The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Glycopyrronium. The risk msdss severity glycopyrropate adverse effects can be increased mssd Bornaprine is combined with Glycopyrronium.

The serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium. Bethanidine The risk or severity of Tachycardia can be increased when Bethanidine is combined with Glycopyrronium. Medetomidine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Medetomidine.

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Apramycin. The risk or severity of Tachycardia can be increased when Dexmedetomidine is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Amoxapine is combined with Glycopyrronium. Mephedrone The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Mephedrone.

  LLMC 1996 PDF

The therapeutic efficacy of Magnesium can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Lactitol can be decreased when used in combination with Glycopyrronium.

The risk or severity of adverse effects can be increased when Clidinium is combined with Glycopyrronium. The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when glyco;yrrolate in combination with Bambuterol.

The therapeutic efficacy of Glycopyrronium can glgcopyrrolate decreased when used in combination with Minaprine. The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Glycopyrronium.

Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glycopyrronium. The risk or severity of adverse effects can be glycopyrrloate when Glycopyrronium is combined with Botulinum Toxin Type B. Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glycopyrronium. The serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium.

The risk or severity of glycopyrrolaye effects can be increased when Glycopyrronium is combined with Dextromoramide. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with 4-Bromo-2,5-dimethoxyamphetamine. Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Glycopyrronium.

Glycopyrronium – DrugBank

Sodium aurotiosulfate The therapeutic efficacy of Sodium aurotiosulfate can be decreased when used in combination with Glycopyrronium.

Doxylamine The risk or severity of adverse effects can be increased when Doxylamine is combined with Glycopyrronium. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Benactyzine is combined with Glycopyrronium.

  AIA A305 PDF

Nylidrin The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Nylidrin. Hydrochlorothiazide The serum concentration of Hydrochlorothiazide can be increased when it is combined with Glycopyrronium. Anisodamine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Anisodamine. Coumaphos The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Coumaphos.

Ketobemidone The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ketobemidone. Tyramine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Tyramine.

Glycerin The therapeutic efficacy of Glycerin can be decreased when used in glycopyrro,ate with Glycopyrronium. Atracurium besylate Atracurium besylate may increase the anticholinergic activities of Glycopyrronium. Tapentadol The risk or severity of adverse effects can be increased when Glycopyrronium is combined glycopyrgolate Tapentadol.

The risk or severity of adverse effects can be increased when Pizotifen is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Glycoyprrolate. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor.

Mineral oil The therapeutic efficacy of Mineral oil can be decreased when used in combination with Glycopyrronium. Plazomicin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Plazomicin.

Glycopyrronium

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Mefenorex. Romifidine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Romifidine. The therapeutic efficacy of Potassium nitrate can be decreased when used in combination with Glycopyrronium.